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Abstract
Introduction: Targeted therapy directed at specific molecular alterations is already creating a shift in the treatment of cancer
patients. Malignant gliomas commonly overexpress the oncogenes EGFR and PDGFR and contain mutations and deletions
of the tumor suppressor genes PTEN and TP53. Some of these alterations lead to activation of the P13K/Akt and Ras/MAPK
pathways, which provide targets for therapy. Perillyl alcohol (POH), the isoprenoid of greatest clinical interest, was initially
considered to inhibit farnesyl protein transferase. Follow-up studies revealed that POH suppresses the synthesis of small
G proteins, including Ras. Intranasal delivery allows drugs that do not cross the blood-brain barrier to enter the central ner-
vous system. Moreover, it eliminates the need for systemic delivery, thereby reducing unwanted systemic side effects.
Materials and Methods: Applying this method, a phase I/II clinical trial of POH was performed in patients with relapsed
malignant gliomas after standard treatment: surgery, radiotherapy, and chemotherapy. POH was administrated in a concen-
tration of 0.3% volume/volume (55 mg) four times daily in an interrupted administration schedule. The objective was to eval-
uate toxicity and progression-free survival (PFS) after six months of treatment. The cohort consisted of 37 patients, includ-
ing 29 with glioblastoma multiforme (GBM), 5 with grade III astrocytoma (AA), and 3 with anaplastic oligodendroglioma
(AO). Neurological examination and suitable image analysis (computed tomography (CT), magnetic resonance imaging
(MRI)) established disease progression. Complete response was defined as neurological stability or improvement of condi-
tions, disappearance of CT/MRI tumor image, and corticosteroid withdraw; partial response (PR) as ≥50% reduction of
CT/MRI tumor image, neurological stability, or improvement of conditions and corticosteroid requirement; progressive
course (PC) as ≥25% increase in CT/MRI tumor image or the appearance of a new lesion; and stable disease as a lack of any
changes in the CT/MR tumor image or neurological status. 
Results: After six months of treatment, PR was observed in 3.4% (n=1) of the patients with GBM and 33.3% (n=1) with
AO; stable disease in 44.8% (n=13) with GBM, 60% (n=3) with AA, and 33.3% (n=1) with AO; and PC in 51.7% (n=15)
with GBM, 40% (n=2), with AA and 33.3% (n=1) AO. PFS (sum of PRs and stable disease) was 48.2% for GBM, 60% for
AA, and 66.6% for AO patients. 
Conclusions: The preliminary results indicate that intranasal administration of the signal transduction inhibitor POH is a safe,
noninvasive, and low-cost method. There were no toxicity events and the regression of tumor size in some patients is sug-
gestive of antitumor activity.
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Gliomas form a heterogeneous group of tumors. In
adult patients, most of these can be classified based on
their histopathological features as astrocytic, oligoden-
droglial, oligoastrocytic, or ependymal tumors [6].
Additionally, a malignancy grade is attributed to these
gliomas based on histopathological features including
nuclear atypia, mitotic activity, microvascular prolifera-
tion, and necrosis. Although histopathological classifica-
tion is still the gold standard guiding therapy of glioma
patients, it is increasingly clear that different genetic
subtypes exist within these subgroups and that specific
molecular genetic changes are of prognostic signifi-
cance. Molecular analysis revealed that genetic alter-
ations and pathways may differ between the different
histopathological types: whereas a gain of chromosome
7p and a loss of chromosome 10q are considered to be
characteristic for glioblastoma multiforme (GBM;
WHO grade IV astrocytoma – AA) [18], losses of
1p and 19q are most frequently detected in oligoden-
drogliomas [20]. In addition it was shown that different
genetic subtypes exist even within the specific
histopathological groups: secondary GBMs that develop
via progression from a less malignant lesion frequently
show p53 mutations, LOH 17p, and overexpression of
PDGFR, while primary GBMs that occur without clini-
cal evidence of a precursor lesion are often character-
ized by amplification or overexpression of EGFR [13]. 
For the above reasons, research efforts have focused
on the investigation of molecular alterations in neoplas-
tic glia, aiming at the identification of novel and more
specific therapeutic targets. Such alterations often result
from multiple mutations in proto-oncogenes and tumor-
-suppressor genes [25], which encode for proteins that
play important roles in signal transduction. In this con-
text, recent discoveries have shed light on the molecular
events driving glioma growth, including abnormalities of
three major molecular pathways: extracellular growth
factors and their receptors EGF/EGFR and
PDGF/PDGFR and the signal transduction cascades
Ras and AKT [21]. Therapies targeting these specific
molecules may result in killing tumor cells effectively
while keeping normal cells intact. 
The Ras pathway as a target for glioma therapy 
Ras is an integral signaling element and has been
characterized as the primary switch that transmits exter-
nal signals through numerous intracellular signaling
pathways. In mammalian cells, three ras genes encode
four Ras isoforms (H-Ras, K-Ras4A, K-Ras4B, and N-
-Ras) that are highly homologous but functionally dis-
tinct. Ras proteins are a class of nucleotide-binding pro-
teins that play pivotal roles in the control of normal and
transformed cell growth [26]. Experimental studies on
Ras protein structure, function, and regulation indicate
that they are key intermediates in signal transduction
pathways that mediate proliferative and other types of
signal largely upstream from receptor kinases, which
control a wide variety of cellular processes including
growth, differentiation, apoptosis, cytoskeletal organi-
zation, and membrane trafficking [28]. For Ras to trans-
duce the extracellular signals provided by growth factors
and cytokines, it must be associated with the inner sur-
face of the plasma membrane. Ras proteins are a family
of membrane-associated small GTPases that transmit
signals from cell surface receptors such as EGFR,
EGFRvIII, and PDGFR, promoting diverse cellular
effects such as proliferation, survival, and angiogenesis
[30]. The membrane anchorage of Ras, required for
functional activity in signal transduction, is facilitated by
post-translational modifications resulting in covalent
attachment of a farnesyl group to the cysteine in the C-
-terminal CAAX motif. This attachment is mediated by
farnesyltransferase (FTase). These lipophilic modifica-
tions facilitate the association of isoprenylated proteins
with an intracellular membrane, which is a functional
requirement. Farnesylation of Ras enhances its ability
to stimulate downstream signaling enzymes, including
mitogen-activated protein kinase in mammalian cells.
Unfarnesylated Ras proteins do not associate the plas-
ma membrane and are incapable of cellular transforma-
tion [6].
FTase inhibitors represent a new class of agents that
target signal transduction pathways responsible for the
proliferation and survival of diverse malignant cell
types. Although these agents were developed to prevent
a processing step necessary for membrane attachment
and maturation of Ras proteins, recent studies suggest
that FTase inhibitors block the farnesylation of addi-
tional cellular polypeptides, thereby exerting antitumor
effects independent of the presence of activating ras
gene mutations [21]. Even though GBMs do not display
ras mutations, they may have enhanced expression of
Ras. Also, GBMs expressed high levels of ligand-depen-
dent and -independent growth factor (EGF and PDGF)
receptors. Activation of these receptors leads to tyrosine
kinases activation and functional up-regulation of the
Ras signaling pathway or expresses the activated form of
this protein [20]. Overexpression and activation of
receptor tyrosine kinases, such as PDGFR and EGFR,
lead to the proliferation of human malignant AA cells.
Although oncogenic mutations affecting Ras are not
prevalent in human malignant AAs, they might be ele-
vated in these tumors secondary to the mitogenic signals
originating from activated receptor tyrosine kinases
[20]. Furthermore, blocking Ras activation by expres-
sion of the Ha-Ras-Asn dominant-negative mutant or by
farnesyl transferase inhibitors decreased the in vitro pro-
liferation of the human AA cell lines [14]. These results
support the hypothesis that proliferative signals from
receptor tyrosine kinases expressed by human malignant
AA cells utilized the Ras mitogenic pathway [14].
Pharmacological inhibitors of the Ras pathway may
therefore be of therapeutic value in these currently ter-
minal tumors. Previous studies have demonstrated that
AAs express elevated levels of activated Ras.GTP
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Overall, the current data suggest that activation of the
Ras signaling pathway in malignant gliomas is due to
aberrant expression and overactivity of membrane tyro-
sine kinase receptors, including EGFR, PDGFR,
FGFR, and IGF-IR.
Perillyl alcohol-inhibition of the Ras/MAPK pathway
The search for new chemotherapeutic drugs has
increased, especially for those that have a natural origin.
POH, also known as p-metha 1,7-diene-6-ol and some-
times as 4-isopropenyl-cyclohexenecarbinol, is com-
posed of two isoprene units produced by the mevalonate
pathway. Diverse mevalonate-derived products of sec-
ondary metabolic pathways present in plants have both
chemotherapeutic and chemopreventive properties.
The mevalonate pathway produces isoprenoids that are
vital for diverse cellular functions, ranging from choles-
terol synthesis to growth control. Several mechanisms
for the feedback regulation of low-density-lipoprotein
receptors and of two enzymes involved in mevalonate
biosynthesis ensure the production of sufficient meval-
onate for several end products [5]. Manipulation of this
regulatory system could be useful in treating certain
forms of cancer [10]. It has been found to be active in
inducing apoptosis in tumor cells with no impact on nor-
mal cells and can in fact turn back tumor cells to a dif-
ferentiated state [31].
Although the mechanism by which POH exerts its
anti-cancer activity is not clear, a number of potentially
important drug-related activities have been observed in
preclinical studies, including cellular effects such as an
early G1 arrest and the induction of apoptosis and bio-
chemical effects such as the inhibition of post-transla-
tional modification of proteins involved in signal trans-
duction. Indeed it has been postulated that the anti-car-
cinoma activity of POH involves a decrease in the levels
of isoprenylated Ras and Ras-related proteins, thereby
reducing the physiological functioning of these proteins
[16]. Protein isoprenylation involves the post-translation-
al modification of a protein by the covalent attachment
of a lipophilic farnesyl isoprenoid group to a Cys residue
at or near the carboxyl terminus. Isoprenoid substrates
for prenylprotein transferase enzymes include farnesyl
pyrophosphate plus geranylgeranyl pyrophosphate, two
intermediates in the mevalonate pathway [1]. This action
was widely attributed to the inhibition of farnesyl protein
transferase activity. Farnesylation is the most critical part
of the process that leads to the activation of Ras, and far-
nesyl transferase inhibitors exert their antitumor effect
in part by inhibiting Ras-mediated signaling [22]. A study
showed that on H-Ras vs. K-Ras farnesylation was inhib-
ited by perillyl alcohol (POH) [30]. Also, follow-up stud-
ies revealed that POH suppresses the synthesis of small
G proteins and 3-hydroxy-3-methylglutaryl coenzyme
A reductase [17]. 
Our experiments [7] showed that in vitro treatment
with POH consistently inhibited proliferation, produced
marked changes in cell morphology, inhibited protein
synthesis, and caused marked alteration in membrane
permeability and drastic changes in the cytoarchitecture
of C6, U87MG, and A172 cells. We previously showed
that with in vivo treatment of glioblastoma cells, POH
showed inhibition of cell migration and anti-metastatic
activity in the model of the chick embryo with the C6
cell line [31]. Such results indicate the chemotherapeu-
tic action of POH by promoting cytotoxicity and arrest-
ing migration of murine and human glioblastoma cell
lines. Also, another study of our group [12] showed that
treatment of both human primary cultures and estab-
lished cell lines of GBM (U87 and A172) with 1 mM of
POH led to marked alterations in cell morphology,
decreased cell viability, and death by apoptosis. Given
the limited toxicity of POH in humans, its proven effica-
cy in several animal models, and its potential to inhibit
Ha-ras farnesylation, we conducted a new method for
POH administration, i.e. POH inhalation. This intra-
nasal administration allows POH to cross the blood-
brain barrier (BBB) and reach the central nervous sys-
tem (CNS), eliminating the need for systemic delivery
and reducing the side effects. 
Based on the favorable therapeutic ratio observed
with in vitro and in vivo treatment, commercial availabil-
ity, low cost, and low toxicity, we developed a phase I/II
clinical trial that delivers POH by inhalation to patients
with relapsed malignant gliomas. This trial was
approved by the Brazilian Committee of Ethics and
Research (CONEP 9681 no. 25000.009267/2004-25, July
12, 2004).
MATERIALS AND METHODS
This study was approved by the Ethics Council of
Hospital Universitario Antonio Pedro-Universidade
Federal Fluminense (UFF). Informed consent was
obtained from either the patient or next of kin. 
Patient selection
To be selected, patients had to have histopathologi-
cal diagnosis of malignant glioma. This was done during
the first surgery. Thirty-seven patients with recurrent
malignant gliomas were enrolled in this trial. No effec-
tive standard therapy was available for any patient who
gave informed written consent for the POH protocol,
according to CONEP 9681 no. 25000.009267/2004-25
approved on July 12, 2004. Patients with relapsed malig-
nant gliomas, aged older than 18 years, had measurable
contrast-enhancing tumor on magnetic resonance imag-
ing (MRI), Karnofsky performance scale of 70% or
higher, adequate bone marrow function, white blood
cell count of 3000/µl or higher, absolute neutrophil
count of 1500/µl or higher, platelet count of
100,000/µl or higher, hemoglobin of 8.0 g/dl or higher,
bilirubin of 0.3 mg/dl or higher, serum glutamic
oxaloacetic transaminase not more than twice the upper
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than twice the ULN, and serum creatinine of 1.6 mg/dl
or less as well as stable heart rhythm, no unstable angi-
na, no clinical evidence of congestive heart failure, no
radiation therapy or chemotherapy within 4 weeks of
initiation of therapy, and no mitomycin or nitrosoureas
within six weeks. Pregnant women, patients with hema-
tological malignancy, and patients taking antiepileptic
drugs known to be metabolized by the cytochrome 
P-450 system were excluded. Patients were not allowed
to take cholesterol-lowering agents during the study.
Drug formulation
POH was supplied by Hospital Universitário
Antonio Pedro-UFF and formulated for inhalation by
the Pharmacia Universitária-UFF according to the BR
Application Number 0107262-5 December 17, 2001.
Drug administration and dose escalation
Our previous study showed anti-metastatic activity
of POH when C6 murine glial cells were exposed to con-
centrations of 0.3–0.03% POH [31]. Applying this con-
centration, our group studied POH intranasal adminis-
tration in C57BL6 mice. This study showed that POH
intranasal administration increased the lymphoid popu-
lation in the broncoalveolar lavage and activated some
of innate immunity, suggesting a possible role for POH
as a chemotherapeutic drug also in pathological
processes affecting the lung [29]. In our clinical trial all
the patients received 0.3% v/v POH (55 mg) four times
daily by intranasal delivery, totaling 220 mg/day. Owing
to the efficacy of the intranasal delivery used in our trial,
we decided to use 0.3% POH 55 mg four times daily as
the first dose escalation. 
Outcome
Complete response was defined as neurological sta-
bility or improvement of conditions, disappearance of
computed tomography (CT)/MRI tumor image, and
corticosteroid withdraw; partial response (PR) as ≥50%
reduction of CT/MRI tumor image, neurological stabil-
ity, or improvement of conditions and corticosteroid
requirement; progressive course as ≥25% increase in
CT/MRI tumor image or the appearance of a new
lesion; and stable disease as a lack of any changes in the
CT/MRI tumor image or neurological status.
RESULTS
Patient characteristics
Thirty-seven patients with recurrent malignant
gliomas were enrolled, including 29 patients with GBM,
5 patients with grade III AA, and 3 patients with
anaplastic oligodendroglioma (AO). The ages of the
patients with GBM ranged from 38–62 (median: 50), with
AA from 41–64 (median: 52.5), and with AO from 35–69
(median: 52) years. Before entering the clinical trial, all
the patients received prior conventional therapy (surgery,
chemotherapy, and radiotherapy), were out of therapeu-
tic possibilities, and presented recurrence (Table 1).
Outcome
With a medium follow-up of 48 weeks, the six-month
progression-free survival (PFS; partial responses and
stable disease) rate for the patients with GBM was
48.2% patients (Table 2 and Fig. 1). Patients with AA
and AO had a significantly better rate than the patients
with GBM (Fig. 1). Time to progression and overall sur-
vival were measured from treatment initiation and ana-
lyzed by the Kaplan-Meier method including 95% con-
fidence intervals (Fig. 2). 
In the 29 patients with GBM, 13 showed stable dis-
ease and 15 showed PD (Fig. 3 and Table 2). All
patients were were receiving corticosteroids 4 mg/6
h orally before entering the clinical trial. The corticos-
teroid was maintained during POH treatment in all
patients. The dose of corticosteroid was decreased in
the patients who presented improvement of clinical sta-
tus. One patient died decurrently of septic fever, three
patients of pneumonia, and one patient of thromboem-
bolism. In one patient with recurrent GBM after six
months of treatment with POH and steroid therapy pre-
sented fever and seizures. CT scan revealed a brain
abscess. The patient underwent a right temporal-pari-
etal craniotomy for removal of both the abscess and the
rest of the recurrent tumor. The anatomopathological
examinations are show in Fig. 4. Tumor samples
obtained from the first and second surgical procedures
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Table 1. Patients’ characteristics
GBM AA AO
(n=29) (n=5) (n=3)
Age, years
median 50  52.5  52
range 38–62  41–64  35–69
Sex
male 19  3  1
female 10  2  2 
Prior treatment regimens
prior radiotherapy  29  5  3
prior chemotherapy agents  29  5  3
anti-epileptic drug  29  5  3
prior corticosteroid intake  29  5  3
KPS
100 0  0  0
90 14  3  2
80 13  1  1
70 2  1  0
Abbreviations: Anti-epileptic drug – phenytoin, phenobarbi-
tal, carbamazepine; GBM – glioblastoma multiforme; 
AA – anaplastic astrocytoma; AO – anaplastic oligoden-
droglioma; KPS – Karnofsky performance status.
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detected in the sample from the first surgery. In con-
trast, cells positive for both TUNEL and caspase-3 were
detected in the sample following POH treatment (Fig. 4). 
In the 5 patients with AA, 3 showed stable disease
and 2 showed PD (Fig. 3 and Table 2). One patient with
AO showed PR and remained alive without recurrence
and no corticosteroids intake, 1 showed PD, and 1
showed stable disease (Fig. 3 and Table 2). 
Toxicity of POH intranasal administration
All the patients were submitted to the toxicity tests
required by National Cancer Institute Common Toxicity
Criteria version 3 for this kind of clinical trial.
Laboratory exams and images of the thorax, brain, and
abdominal cavity were normal. Indeed, we now have 6
patients with more than one year of POH. None of them
presents any signs of toxicity. POH intranasal delivery
was well tolerated in all patients. No dose reduction or
drug discontinuation was required for any of the study
participants.
DISCUSSION
Over the past three decades we have made great
strides in the treatment of most, but not all, brain
tumors. Dramatic advances have occurred in diagnostic
imaging, neurosurgery, neuroanesthesia, radiotherapy,
and chemotherapy for CNS tumors. Unfortunately, our
progress has not yet met our expectations. Because of
the infiltrative nature of most primary brain tumors,
neurosurgery can never be expected to be curative for
the majority of gliomas. Because infiltrative tumors
interdigitate with normal brain cells and are not highly
sensitive to irradiation, one cannot expect radiotherapy
to be curative without serious damage to normal brain
cells. The hope for a cure, then, rests with chemothera-
py. The ability to treat most advanced malignancies with
classical cytotoxic DNA-damaging agents is limited,
with little curative potential and rare durable remissions
[15]. This has led to emphasis on the development of
new therapeutic agents with novel mechanism of action.
Cancer researchers now have a unified concept to
guide their search for specific genetic abnormalities.
The genes and proteins that participate in the conver-
sion of normal into malignant cells are also involved in
the key processes that convert extracellular events that
culminate in division and growth [27]. Malignant
gliomas commonly overexpress EGF receptor and its
ligand-independent mutant EGFRvIII. This results in
signaling through the Ras-MAPK and PI3K/Akt path-
ways [23]. Data showing that POH inhibits the prenyla-
tion of Ras and other proteins in many cell types [30]
indicate that POH may be effective against glioma cells.
In fact, our in vitro and in vivo experiments showed that
POH induced marked changes in cell morphology,
induced apoptosis, and led to inhibition of angiogenesis
and migration of glioma cell lines and explanted cells
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Table 2. Parameters of efficacy in six months of POH treat-
ment in patients with malignant gliomas
GBM AA AO
(n=29) (n=5) (n=3)
Follow-up, weeks  48  48  56
Six-month progression-free survival 48.2% 60% 66.6%
Radiographic responses
complete responses 0  0  0
partial responses  1  0  1
stable disease  13  3  1
progressive disease  15  2  1
Patients w/no corticosteroid intake 
at 6 month  0  0  0
1 year  1  0  1
Fig. 1. Progression-free survival (sum of patients with partial
response and stable disease) for all 37 patients treated with POH
intranasal delivery. The median PFS rate was 48.2% for patients
with GBM, 60% for patients with AA and 66.6% for patients with
AO. Abbreviation: GBM – glioblastoma multiforme; AA –
anaplastic astrocytoma; AO – anaplastic oligodendroglioma; PD –
progressive disease; PR – partial response; SD – stable disease.
Progression free survival at month 6
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0
Fig. 2. Kaplan-Meier estimate of PFS for patients with GBM and
AA.
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Fig. 3. Response evaluation of a total of 37 patients on the sixth month. Twenty-nine patients with GBM: 1 with PR, 13 with SD and 15 with
PD; 5 patients with AA: 3 with SD and 2 with PD; 3 patients with AO: 1 with PR, 1 with SD and 1 with PD.
A B C D
E F G H
Fig. 4. Apoptotic responses in human recurrent glioblastoma multiforme treated with intranasal administration of POH. A: initial GBM; B:
Astrocytic tumor of the highest grade with dense cellularity and striking pleomorphism (HE×100); C, D: treated initial GBM by activated
caspase-3 immunohistochemistry and terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick-end labeling (TUNEL). We
found apoptotic cells in the treated tumor G: by activated caspase-3 immunohistochemistry and H: terminal deoxynucleotidyl-mediated
deoxyuridine triphosphate nick-end labeling (TUNEL); E: computed tomography demonstrating a recurrent glioblastoma after radiation
therapy and response to intranasal delivery of perillyl alcohol after 6 months treatment; F: scattered apoptotic cells (tumor cells) related to
the areas with radiation and POH treatment effects (HE×400).
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Fig. 5. Preoperative MRI revealing the extent of the
tumor in the right hemisphere (A). Computed
tomography demonstrating a recurrence of tumor
after surgery and radiation therapy (B). Response to
intranasal delivery of POH after 3 (C) and 6 months
(D) treatment. We can observe persistent peritu-
moral edema.
A B
C
D
from a patient with GBM [7, 12, 31]. Also, studies from
our group indicate that POH may induce regression in
patients with GBM [8, 9]. Studies of phase I and II clin-
ical trials with POH administered orally indicated that
POH may have a tumoristatic effect and that the opti-
mal schedule of administration would result from con-
tinuous drug exposure [2, 3]. However, these studies
also showed toxicities, consisting of nausea, early satiety,
eructation, and unpleasant taste as well as fatigue. The
chronic nature of these toxicities led to problems with
patient tolerance and compliance, suggesting that oral
consumption of POH is an unpleasant experience for
most patients. Our studies showed that the intranasal
formulation of POH was generally well tolerated and
relatively well absorbed. In some patients, this thera-
peutic strategy led to an increase in PFS and decrease in
tumor size, as evidenced by MRI. It is interesting to note
that in our study we investigated whether the partial
regression observed in a patient with a recurrent GBM
after treatment by intranasal delivery of POH four times
daily, is mediated by apoptosis. Data from classical his-
tology, terminal deoxynucleotidyl-mediated deoxyuri-
dine triphosphate nick-end labeling (TUNEL) assay, as
well as activation of caspase-3, showed increased apop-
tosis in the treated tumor (Fig. 4). 
A study [24] showed that temozolomide schedules
deplete O6-methylguanine methyltransferase and may
overcome chemoresistance. This study enrolled 19
patients (15 with anaplastic AA, 4 with AO) who
received temozolomide (100 mg/m2/day for 21 consecu-
tive days every 28-day cycle) at first recurrence, either
until disease progression or for 12 cycles. Six-month PFS
was 56%, comparing favorably with historic controls
treated with the standard 5-day temozolomide schedule.
Median survival was 12.9 months (95% confidence
interval: 3.7–22 months). Among 15 evaluable patients,
2 had a complete or PR and 10 had stable disease.
Grades 3 and 4 lymphopenia occurred in 53% and 47%
of the patients, respectively. However, treatment of
recurrent malignant gliomas with intranasal delivery of
POH achieved at six-month PFS was 48.2% for patients
with GBM, 60% for patients with AA, and 66.6% for
patients with AO. It is important to note that after 12
months of treatment with POH by intranasal delivery, 3
patients with malignant gliomas presented with consid-
erable reductions in tumor mass and compression
effects and 2 patients, 1 with GBM and 1 with AO,
ceased corticosteroid intake. There were no toxicity
events.
A common property of brain tumors is their ability
to cause edema in the surrounding brain. Edema forms
as a result of a leaky BBB and persists when the brain
fails to clear the excess fluid. It is a significant source of
morbidity and mortality. Although the experimental use
of POH intranasal delivery in patients with refractory
high-grade malignant gliomas has indeed led to some
clinical responses, MRI offers evidence that there is no
regression in edema peritumoral (Figs. 5 and 6).
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ciation of the underlying molecular biology of malignant
gliomas, we remain ignorant of many crucial aspects of
glioma biology. Regulators of tumor invasion escape
immune targeting and neo-angiogenesis remains to be
elucidated. An invasive and hypoxic tumor shows resis-
tance to traditional therapies and, probably, targeted
therapies. It is increasingly evident that a greater under-
standing of the molecular mechanisms of gliomagenesis
is needed to improve treatments for these patients.
Rather than being paralyzed by these intricacies, the
neuro-oncology community, pharmaceutical companies,
and governmental regulatory agencies will need to
attack these issues head-on. Success in changing the out-
come of malignant glioma depends on refining our
understanding of the biology and biochemistry of brain
tumors, enabling us to develop new therapeutic oppor-
tunities against this disease.
In view of the fact that the proliferative signaling of
human high-grade gliomas seems to utilize p21-Ras-
-mediated signal transduction, the concept of using p21-
-Ras pathway inhibition, whether by prenylation block-
ade or by other pharmacological approaches, as an adju-
vant or single therapy appears to be attractive. POH
intranasal administration is safe, noninvasive, and low-
-cost and regression of tumor size in some patients is
suggestive of antitumor activity. However, it should also
be taken into account that human tumors often contain
multiple oncogenic mutations at the time of diagnosis.
These may occur in upstream signaling elements such as
the EGF receptor and Ras and/or in downstream ele-
ments such as Raf-1, the MAPK cascade. In addition,
neoplastic cells can activate various alternative signaling
routes upon blockage of Ras. Therefore it may be too
much to expect that Ras therapies alone can be success-
ful against high-grade malignant gliomas in the clinic.
Perhaps such therapies may be studied in combination
with other treatment modalities such as VEGF, mTOR,
PDGFR, and EGFR inhibitors. In this regard the inter-
action of neoplastic cells with the peritumoral stroma
can also result in the disruption of tissue homeostasis.
Tumor burden frequently results in the recruitment of
leukocytes to the tumor site (through cytokines and
chemokines), which leads to an inflammatory reaction.
Such approaches may help further refine our under-
standing of the biology and biochemistry of brain
tumors, enabling us to develop new therapeutic oppor-
tunities against this disease.
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Fig. 6. Magnetic resonance imaging (MRI) showing the effect to intranasal delivery of POH treatment in a patient with relapsed glioblas-
toma. Note the persistent peritumoral edema between the initial MRI (A, D) and the follow-up performed after 6 months (B, E) and after
18 months (C, F) of treatment.
A B C
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